Download PDF
Thromb Haemost 1976; 35(02): 382-385
DOI: 10.1055/s-0038-1647932
Original Article
Schattauer GmbH

Changes in Human Amniotic Fluid Fibrinolytic Inhibitor Levels during Pregnancy

J Aznar
1   Department of Clinical Pathology and Department of Obstetrics and Gynecology. Ciudad Sanitaria “La Fe”, Valencia, Spain.
,
A Hernandez
1   Department of Clinical Pathology and Department of Obstetrics and Gynecology. Ciudad Sanitaria “La Fe”, Valencia, Spain.
,
J.J Parrilla
1   Department of Clinical Pathology and Department of Obstetrics and Gynecology. Ciudad Sanitaria “La Fe”, Valencia, Spain.
,
A Estelles
1   Department of Clinical Pathology and Department of Obstetrics and Gynecology. Ciudad Sanitaria “La Fe”, Valencia, Spain.
,
J Gilabert
1   Department of Clinical Pathology and Department of Obstetrics and Gynecology. Ciudad Sanitaria “La Fe”, Valencia, Spain.
› Author Affiliations
Further Information

Publication History

Received 03 June 1975

Accepted 20 June 1975

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

Summary

The amniotic fluid (AF) when incubated with the patient’s own plasma diminishes the lytic activity of the plasma. It is suggested that this inhibition is due to the presence of fibrinolytic inhibitors in the AF. The inhibitors rate increases as pregnancy advances. Evaluating these inhibitors in a group of 65 women before and after the 38th week of pregnancy, a higher rate of fibrinolytic inhibitors is found after the 38th week. The said differences are statistically significant. For the moment it does not seem that the increasing of the inhibitors in the last part of pregnancy might be used as a fetal maturity test.

 

  • References

  • 1 Albrechtsen O. D, Trolle D. 1955; A fibrinolitic system in human amniotic fluid. Acta Haemotologica 14: 376.
    PubMedGoogle Scholar
  • 2 Astrup T, Mullerzt S. 1952; The fibrin plate method for estimating fibrinolytic activity. Archives of Biochemistry and Biophysics 40: 346.
    CrossrefPubMedGoogle Scholar
  • 3 Aznar J. 1972. Sindrome de Coagulación Intravascular Diseminada. In Ciscar F, Farreras P. (eds.) Diagnostico Hematologico . Jims.; Barcelona: p. 1867.
    Google Scholar
  • 4 Bonnar J. 1973; Blood Coagulation and Fibrinolysis in Obstetrics. Clinics in Haematology 2: 213.
    PubMedGoogle Scholar
  • 5 Courtney L. D, Allington M. 1972; Procoagulant properties of amniotic fluid. American Journal of Obstetrics and Gynecology 113: 911.
    CrossrefPubMedGoogle Scholar
  • 6 Hawkey C. M, Stafford J. L. 1964; A standard clot method for assay of plasminogen activators anti-activators and plasmin. Journal of Clinical Pathology 17: 175.
    CrossrefPubMedGoogle Scholar
  • 7 Hernandez A, Parrilla J. J, Aznar J, Gilabert J, Estelles A. 1975. Valoración de la actividad fibrinolítica del líquido amniótico. Sangre; (in press).
    Google Scholar
  • 8 Peterson E. P, Taylor H. B. 1970; Amniotic fluid embolism: an analysis of 40 cases. Obstetrics and Gynecology 35: 787.
    PubMedGoogle Scholar
  • 9 Phillips L. L, Davidson E. C. 1972; Procoagulant properties of amniotic fluid. American Journal of Obstetrics and Gynecology 113: 911.
    CrossrefPubMedGoogle Scholar
  • 10 Pritchard J. A. 1973; Haematological Problems Associated with Delivery, Placental Abruption, Retained Dead Fetus and Amniotic Fluid Embolism. Clinics in Haematology 2: 563.
    PubMedGoogle Scholar
  • 11 Uszynski M, Uzynski-Folejewska R. 1969; Plasminogen activator and urokinasa inhibitor in myometrium placenta and amniotic fluid. American Journal of Obstetrics and Gynecology 105: 1041.
    CrossrefPubMedGoogle Scholar
  • 12 Weiner A. E, Reíd D. E, Roby C. C. 1949; Hemostatic activity of amniotic fluid. Science 110: 190.
    CrossrefPubMedGoogle Scholar